Pseudomonas aeruginosa in the ICU: Prevalence, resistance profile, and antimicrobial consumption
Tipo
Artigo
Data de publicação
2020
Periódico
Revista da Sociedade Brasileira de Medicina Tropical
Citações (Scopus)
15
Autores
Ribeiro A.C.D.S.
Crozatti M.T.L.
da Silva A.A.
Macedo R.S.
Machado A.M.O.
Silva A.T.A.
Crozatti M.T.L.
da Silva A.A.
Macedo R.S.
Machado A.M.O.
Silva A.T.A.
Orientador
Título da Revista
ISSN da Revista
Título de Volume
Membros da banca
Programa
Resumo
© 2020, Sociedade Brasileira de Medicina Tropical. All rights reserved.Introduction: Pseudomonas aeruginosa is one of the main pathogens causing infection in intensive care units (ICUs) and usually presents antimicrobial resistance. Methods: Data were obtained from ICUs between 2010 and 2013. Results: P. aeruginosa had a prevalence of 14.5% of which 48.7% were multidrug resistant. We observed increasing resistance to carbapenems and polymyxin B and growing consumption of aminoglycosides, meropenem, ceftazidime, and polymyxin B. The regression impact between resistance and consumption was significant with respect to amikacin, imipenem, meropenem, and polymyxin B. Conclusions: Monitoring antimicrobial consumption and resistant microorganisms should be reinforced to combat antimicrobial-and multidrug resistance.
Descrição
Palavras-chave
Assuntos Scopus
Anti-Bacterial Agents , Cross Infection , Drug Resistance, Multiple, Bacterial , Humans , Intensive Care Units , Microbial Sensitivity Tests , Prevalence , Pseudomonas aeruginosa , Pseudomonas Infections